NextCure (NASDAQ:NXTC) & Viking Therapeutics (NASDAQ:VKTX) Head-To-Head Comparison

Viking Therapeutics (NASDAQ:VKTX) and NextCure (NASDAQ:NXTC) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Profitability

This table compares Viking Therapeutics and NextCure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
NextCure	N/A	-154.62%	-100.19%

Earnings & Valuation

This table compares Viking Therapeutics and NextCure”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64 million	($4.66)	-7.27
NextCure	N/A	N/A	-$55.84 million	($8.70)	-0.72

Viking Therapeutics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Viking Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, NextCure has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.

Insider and Institutional Ownership

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 42.6% of NextCure shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by insiders. Comparatively, 11.9% of NextCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Viking Therapeutics and NextCure, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1	2	8	1	2.75
NextCure	1	1	2	0	2.25

Viking Therapeutics currently has a consensus target price of $96.62, suggesting a potential upside of 185.11%. NextCure has a consensus target price of $19.00, suggesting a potential upside of 202.07%. Given NextCure’s higher probable upside, analysts plainly believe NextCure is more favorable than Viking Therapeutics.

Summary

Viking Therapeutics beats NextCure on 7 of the 12 factors compared between the two stocks.

About Viking Therapeutics

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

About NextCure

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.